Soleno Therapeutics (SLNO) Capital Expenditures (2016 - 2019)
Historic Capital Expenditures for Soleno Therapeutics (SLNO) over the last 6 years, with Q4 2019 value amounting to $5000.0.
- Soleno Therapeutics' Capital Expenditures rose 15000.0% to $5000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $21000.0, marking a year-over-year decrease of 9636.05%. This contributed to the annual value of $218000.0 for FY2024, which is N/A changed from last year.
- Soleno Therapeutics' Capital Expenditures amounted to $5000.0 in Q4 2019, which was up 15000.0% from $6000.0 recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Capital Expenditures registered a high of $570000.0 during Q3 2017, and its lowest value of -$244223.0 during Q4 2015.
- In the last 5 years, Soleno Therapeutics' Capital Expenditures had a median value of $3000.0 in 2016 and averaged $41973.2.
- Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Capital Expenditures was 2840000.0% (2017), while the steepest drop was 20000.0% (2017).
- Over the past 5 years, Soleno Therapeutics' Capital Expenditures (Quarter) stood at -$244223.0 in 2015, then soared by 97.05% to -$7205.0 in 2016, then skyrocketed by 8011.17% to $570000.0 in 2017, then tumbled by 99.65% to $2000.0 in 2018, then skyrocketed by 150.0% to $5000.0 in 2019.
- Its last three reported values are $5000.0 in Q4 2019, $6000.0 for Q2 2019, and $10000.0 during Q1 2019.